Though the linkages between germline mutations of BRCA1 and hereditary breast cancer are well known, recent evidence suggests that altered BRCA1 transcription may also contribute to sporadic forms of breast cancer. Here we show that BRCA1 expression is controlled by a dynamic equilibrium between transcriptional coactivators and co-repressors that govern histone acetylation and DNA accessibility at the BRCA1 promoter. Eviction of the transcriptional co-repressor and metabolic sensor, C terminal-binding protein (CtBP), has a central role in this regulation. Loss of CtBP from the BRCA1 promoter through estrogen induction, depletion by RNA interference or increased NAD + /NADH ratio leads to HDAC1 dismissal, elevated histone acetylation and increased BRCA1 transcription. The active control of chromatin marks, DNA accessibility and gene expression at the BRCA1 promoter by this 'metabolic switch' provides an important molecular link between caloric intake and tumor suppressor expression in mammary cells.
Breast cancer is the second leading cause of death in women worldwide and the number one cause of death from cancer in women age 20-59 (ref. 1) . Individuals harboring germline mutations in the breast cancer susceptibility gene BRCA1 carry an 80% lifetime risk of developing breast cancer 2 . Though very few cases of noninherited sporadic forms of breast cancer are associated with mutation in BRCA1, ~40% of these tumors have a deficiency in BRCA1 expression 3 . Because the majority of these cases do not show hypermethylation of the BRCA1 promoter 4 , a growing consensus has emerged suggesting that a large percentage of sporadic, noninherited breast cancers are associated with altered transcriptional regulation of the BRCA1 gene 3, 5 . The human BRCA1 promoter is bidirectional, controlling divergent transcription of the BRCA1 and NBR2 genes 6 , and many aspects of its regulation have been extensively studied. In addition to methylation of specific CpG residues and islands within the promoter 7 , several groups have demonstrated that the BRCA1 promoter is regulated by a complex and dynamic array of DNA-binding proteins, transcriptional coactivators and transcriptional co-repressors [8] [9] [10] .
The protein product of the BRCA1 gene has many important cellular functions including DNA repair, cell cycle regulation and transcriptional regulation. Accordingly, deficiency in BRCA1 leads to accelerated proliferation, aberrant mitosis, increased chromosome instability and tumorigenesis 11, 12 . BRCA1 transcription is regulated by diverse environmental stimuli including genotoxic agents, hypoxia and mitogenic hormone stimulation. The best-characterized stimulant of BRCA1 expression is estrogen, which induces the highest elevations in BRCA1 mRNA levels, which routinely peak just before the onset of DNA synthesis 13, 14 . In this way, BRCA1 provides a feedback control that monitors and restrains the growth and pro-proliferative effects of estrogen in hormone-responsive tissues [14] [15] [16] . Consequently, disruption of this close opposing relationship with estrogen receptor, in combination with decreased genome stability, accounts for the markedly restricted occurrence of inherited BRCA1-related malignancies in hormone-regulated tissues like breast, ovary and prostate 16 .
The transcriptional co-repressor C terminal-binding proteins (CtBP1 and CtBP2) are members of an evolutionally conserved family of proteins that regulates several different cellular functions in vertebrates 17 . Overexpression of these proteins has been linked to epithelial-mesenchymal transition in breast cancer, a process whose gene expression profile shares many similarities with the molecular signature of BRCA1-deficient tumors [17] [18] [19] . CtBP is a homodimer or heterodimer of CtBP1 and CtBP2 that assembles with a diverse array of factors that regulate chromatin structure. These include the histone deacetylases (HDACs) HDAC1 and HDAC2, the histone acetyltransferases p300 and CBP, and the histone methyltransferase G9a 17 . CtBP can antagonize the expression of multiple tumor suppressors including CDH1 (encoding E-cadherin), CDKN2A (encoding cyclin-dependent kinase inhibitor 2A, also called p16) and PTEN 17 . Most notably, CtBP contains a binding site for NADH that regulates its ability to dimerize, thus establishing CtBP as an important nuclear sensor of cellular metabolic status 20, 21 . We demonstrate here that CtBP assembles at the BRCA1 promoter as part of a dynamic, multicomponent co-repressor complex containing p130, BRCA1 and HDAC1 that represses local histone acetylation at the BRCA1 promoter and BRCA1 transcription. Disruption of this complex by estrogen stimulation and/or changes in NAD + /NADH ratio leads to CtBP dismissal, HDAC1 eviction, increased histone acetylation and subsequent increased BRCA1 transcription from the BRCA1 promoter. These observations define a direct link between cellular metabolic status and the expression of BRCA1 and suggest that caloric intake may selectively influence tumor suppressor function in mammary tissues.
RESULTS
A dynamic co-regulatory complex controls the BRCA1 promoter BRCA1 transcription can be readily induced by exposure to estrogen 13, 14 . We treated MCF-7 cells with 10 nM estradiol for 24 h and found a six-to seven-fold increase in both mature and unspliced (nascent) BRCA1 RNA ( Fig. 1a) . By chromatin immunoprecipitation (ChIP), we found that the BRCA1 promoter shows preloading by a poised RNA polymerase II (Pol II) and p300 histone acetyltransferase (HAT) complex without estrogen stimulation, which is consistent with many promoters in recent genome-wide studies 22 . Neither p300 or Pol II assembly nor activation-associated histone methylation (H3K4Me3) substantially increased from their elevated levels after estrogen stimulation, although binding by the CREB transcription factor increased more notably ( Fig. 1b-d and Supplementary Fig. 1) . Notably, in contrast to Pol II, p300 and histone H3K4Me3, both histone H4 and H3 acetylation substantially increased ( Fig. 1e,f) . These observations suggest that a major regulatory step after estrogen induction at the BRCA1 promoter involves events linked to increased promoter-proximal histone acetylation that occur after the initial recruitment of p300 and the basal transcriptional machinery.
The increase in histone H3 and H4 acetylation at the proximal promoter despite small changes in p300 HAT occupancy suggests that changes in HDAC recruitment may have a role in the estrogeninduced control of BRCA1 expression. Notably, in addition to their direct interactions with the Rb pocket protein family, HDACs can be recruited in the context of several different co-repressor complexes, including Sin3A, NuRD and CtBP 23, 24 . The BRCA1 promoter is negatively regulated by the dynamic assembly of co-repressor complexes containing E2F-1, E2F-4, Rb and Rb-related pocket proteins (for example, p130) and BRCA1 (refs. 9,10,25) . Each of these factors, including BRCA1 itself, can form complexes with HDACs either directly or through interactions involving the CtBP-interacting protein (CtIP) 17, 23, [26] [27] [28] [29] . Accordingly, and consistent with increased histone acetylation at the BRCA1 promoter after estrogen induction, there is a dynamic loss of HDAC1, p130, BRCA1, CtIP, CtBP, E2F-1 and E2F-4 from the BRCA1-proximal promoter after estrogen treatment ( Fig. 2a-e ). Also, in agreement with the interdependent interactions among these components and BRCA1 expression, gene depletion of BRCA1 impairs recruitment of CtBP ( Supplementary  Fig. 2a ) whereas gene depletion of E2F-1 impairs both BRCA1 and CtBP recruitment to the BRCA1 promoter ( Supplementary  Fig. 2b,c) . Furthermore, we detected multiple estrogen-dependent complexes containing BRCA1, CtBP, E2F-4, p130 and p300 by coimmunoprecipitation from nuclear extracts derived from estradiol-treated and untreated MCF-7 cells (Supplementary Fig. 2d ). Together, these observations indicate that BRCA1 transcription is regulated by a multicomponent co-repressor complex containing CtBP that is linked to HDAC1 through multivalent interactions. Disassembly and dismissal of this complex from the BRCA1-proximal promoter, after estrogen stimulation, is a major regulatory step that governs BRCA1 expression.
Finally, consistent with transcriptional regulation by a post-recruitment step, this estrogen-induced dismissal of repressive factors is associated with increased assembly of known elongation factors 30 at the BRCA1 locus, including the negative elongation factor (NELF), the eleven-nineteen lysine-rich leukemia protein (ELL) and the Cdk9 subunit of the positive transcriptional elongation factor b complex (P-TEFb) ( Fig. 2f) . With the exception of NELF, whose assembly at mammalian promoters occurs without traveling with the elongating polymerase 31, 32 , both ELL and P-TEFb are recruited to the BRCA1 locus and show increased distribution into the transcribed region of BRCA1 in coordination with increased histone Lys36 trimethylation marks (H3K36Me3) commonly associated with Pol II elongation 30 ( Fig. 2f and Supplementary Fig. 2e ).
CtBP regulates HDAC1 recruitment and histone acetylation
Thus far, the data demonstrate that complexes containing CtBP have a central role in BRCA1 transcriptional regulation through control of the deposition of chromatin marks at the BRCA1 promoter in response to environmental stimuli via regulation of HDAC1 recruitment. To test for the role of CtBP in this process, we used RNA interference (RNAi) inhibition to suppress CtBP expression ( Fig. 3a) . Upon silencing of CtBP expression in MCF-7 cells, both BRCA1 protein and BRCA1 RNA (nascent and mature) significantly increased. The increased BRCA1 transcription after CtBP depletion is associated with loss of HDAC1 from the BRCA1 promoter and a corresponding increase in histone H3 and H4 acetylation ( Fig. 3b-d A r t i c l e s A r t i c l e s changes occurred with minimal alteration in either Pol II or E2F-1 occupancy at the BRCA1 promoter ( Fig. 3e,f) . The increased BRCA1 induction by CtBP depletion is both geneand promoter-specific as it has minimal effects on BLM expression, inhibits H2AFZ (H2AZ) and MAD3L expression, does not induce the estrogen-responsive TFF1 (pS2) gene (as has been shown 33 ), and does not have a substantial effect on the divergent transcription of the NBR2 gene ( Fig. 4a) . CtBP depletion also mimics the functional influences of BRCA1 overexpression 12 by inducing a cell cycle block in G2 phase ( Fig. 4b) . Finally, CtBP depletion also renders the BRCA1 promoter less responsive to estrogen induction with minimal influence on TFF1 (Supplementary Fig. 3 ), and overexpression of CtBP represses BRCA1 expression without influencing either TFF1 or divergent NBR2 transcription ( Fig. 4c) .
As we described above, the BRCA1 gene is transcribed from a bidirectional promoter 6, 34 . Although most bidirectional promoters have highly correlated bidirectional expression 35 , the expression at the BRCA1 promoter is primarily unidirectional in response to CtBP depletion ( Fig. 3a) and estrogen induction (see below). Therefore, unique aspects of the BRCA1 promoter sequence and chromatin structure may account for the unidirectionality. We tested these possibilities by transient transfection of a bidirectional BRCA1 promoter driving firefly luciferase transcription in the direction of the BRCA1 first exon and Renilla reniformis luciferase transcription in the divergent direction of the NBR2 first exon ( Fig. 4d) . Overexpression of either CtBP or BRCA1 caused bidirectional repression of transcription, suggesting that promoter-and direction-specific repression of BRCA1 transcription by CtBP and BRCA1 requires a structural chromatin context at the endogenous BRCA1 promoter that is not recapitulated by transiently transfected DNA constructs ( Fig. 4d) . To test this, we compared cells transiently transfected with the bidirectional reporter to cells in which the reporter was stably integrated (Fig. 4e) . Return of the BRCA1 bidirectional promoter to a chromatin context recovers the unidirectional transcriptional response to estrogen induction ( Fig. 4e) , thus highlighting the role of chromatin structure in maintaining the fidelity of BRCA1 transcriptional regulation. A r t i c l e s
HDAC inhibition mimics induction by estrogen or CtBP depletion
The mechanism by which CtBP can control BRCA1 transcription involves direct regulation of the local chromatin marks within the BRCA1 bidirectional promoter by preventing histone H3 and H4 acetylation (Figs. 1e,f and 3c,d ) through HDAC1 recruitment ( Figs. 2a and 3b) . If the key regulatory step in this process is histone acetylation, then HDAC inhibition would probably lead to BRCA1 transcriptional induction. This is indeed the case, because incubation of MCF-7 with trichostatin A (TSA) produces a rapid induction of BRCA1 transcription that occurs much earlier than estrogen stimulation for both mature and nascent RNA transcripts ( Fig. 5a and Supplementary Fig. 4) . Also, like estrogen, TCA induction is inhibited by treatment with protein synthesis inhibitors. Notably, the influence of HDAC inhibition is both promoter-specific and directional because neither TFF1 nor NBR2 are substantially induced by HDAC inhibition (Fig. 5a) . Moreover, both estrogen treatment and HDAC inhibition produce nearly identical increases in chromatin accessibility at the BRCA1 promoter compared with the untreated control ( Fig. 5b) . As we expected, HDAC inhibition with TSA leads to substantially increased histone H3 and H4 acetylation at the BRCA1 promoter in addition to some alteration in the assembly of HDAC1, BRCA1 and p130, but does not substantially influence the assembly of CtBP, E2F1 and p300 (Fig. 5c) . These differences suggest that although histone acetylation is a major target, additional protein or factor acetylation may also have a role in the stability of the co-repressor complexes assembled at the BRCA1 promoter ( Fig. 5c and Supplementary Fig. 5a,b) .
Finally, loss of p300 by RNAi depletion renders the BRCA1 promoter unresponsive to TSA treatment and blocks the increase in promoter-proximal histone acetylation, thus demonstrating that p300 is primarily responsible for the positive influence of HDAC inhibition on histone acetylation and transcription at the BRCA1 promoter ( Fig. 5d and Supplementary Fig. 5c ).
CtBP acts as a metabolic switch to control BRCA1 transcription
A unique and biologically important aspect of CtBP is that it is most active as a dimer and its dimerization is promoted by binding to NAD + and NADH 17 . CtBP has a much higher affinity (>100-fold) for NADH compared with NAD + , and the free cellular concentrations of both NAD species approach their CtBP-binding affinities. Because of this, CtBP is both a sensor and an effector of cellular metabolic status 20 . Estrogen treatment is a major form of mitogenic stimulation that increases cellular proliferation in normal mammary tissues and enhances cell cycle entry in breast-derived cell lines like MCF-7 (Supplementary Fig. 6 ). The elevated respiration associated with increased proliferation causes the NAD + /NADH ratio to rise to meet the increased energy demand due to surges in protein synthesis and DNA replication 36, 37 . This is demonstrated by comparison of MCF-7 cells stimulated in the presence of estrogen versus TSA: estrogen stimulation substantially increases the NAD + /NADH ratio (Fig. 6a, left) . The NAD + /NADH ratio can also be increased by treatment with the glycolysis inhibitor 2-deoxyglucose ( Fig. 6a, right) . Most important, increases in NAD + /NADH levels by 2-deoxyglucose treatment selectively lead to increased expression of BRCA1 mature and nascent RNA while having no effect on TFF1 expression or divergent transcription from the NBR2 gene ( Fig. 6b) . Furthermore, the induction of BRCA1 transcription by 2-deoxyglucose is associated with loss of CtBP from the BRCA1 promoter and a concomitant increase in histone H3 and H4 acetylation ( Fig. 6c-e ) without substantial influence on CtBP expression or E2F recruitment (Supplementary Fig. 7) . Finally, although hypoxia blocks BRCA1 transcription in addition to other factors important in the response to DNA damage 9,38 , its influence on estrogen-regulated induction of BRCA1 has not been explored. Because, in contrast to acute 2-deoxyglucose treatment, hypoxia causes a decrease in the NAD + /NADH ratio, it should block estrogen induction of BRCA1 transcription. Hypoxia selectively blocks the induction of BRCA1 transcription by estrogen while influencing neither TFF1 induction nor divergent transcription from the NBR2 promoter (Fig. 7a) . These findings demonstrate that CtBP functions as a metabolic switch at the BRCA1 promoter that selectively controls the levels of histone acetylation, chromatin structure and transcription at the BRCA1 promoter in response to the cell's metabolic status. A r t i c l e s Earlier studies that have mapped nucleosome positioning at the BRCA1 promoter in quiescent and proliferating cells demonstrate that a pronounced shift in locally distributed nucleosomes leads to marked increases in chromatin accessibility 39 . Mapping of the position of the 5′ end or transcriptional start site (TSS) of NBR2 and BRCA1 based on their RefSeq annotation indicates that the intergenic distance between the two NBR2 and BRCA1 TSSs is ~133 bp, which is less than the 147 bp occupied by a single nucleosome. These observations indicate that the bidirectional promoter shared by NBR2 and BRCA1 is effectively occluded by a single, dynamically regulated nucleosome (Fig. 7b) . Thus a central regulatory event that controls BRCA1 expression is an active and persistent competition between DNA-bound transcriptional complexes and the centrally occluding nucleosome, which undergoes cycles of targeted disruption and stabilization by the competing activities of coactivators and co-repressors assembled at the BRCA1 promoter. This balance ultimately influences the accessibility of the promoter to additional positive regulators of the transcription cycle that drive BRCA1 expression.
DISCUSSION
The BRCA1 promoter is regulated by a variety of stimuli, including estrogen stimulation, DNA damage and hypoxia 9, 10, 40 . Each of these processes influences the NAD + /NADH ratio. Estrogen increases the NAD + /NADH ratio secondary to increased respiration due to the proliferative response 37, 41 . Conversely, hypoxia increases NADH levels. DNA damage consumes NAD + through PARP-1 and some forms A r t i c l e s of DNA damage activate the HIPK2 kinase, which phosphorylates CtBP, leading to its elimination via the proteasome pathway 42, 43 . All of these pathways contribute to upregulation of BRCA1 and, consistent with the proposed role of hypoxia and anaerobic glycolysis in promoting tumor formation, suggest a contribution from the downregulation of tumor suppressors in this process 44 . The selective inhibition of estrogen-induced expression of BRCA1 by hypoxia suggests a direct role for this form of regulation during tumor progression in patients with estrogen receptor-positive metastatic breast cancer. Recent reports that PARP-1 assembles at the BRCA1 promoter and that its inhibition represses BRCA1 transcription indicate a potential role for PARP-1 in BRCA1 regulation. Although we detect occupancy of PARP-1 at the BRCA1 promoter in MCF-7 cells, this assembly is constitutive and does not seem influenced by estrogen or HDAC inhibition (Supplementary Fig. 8 ).
Post-recruitment regulation of BRCA1 transcription
The BRCA1 promoter is a member of a unique class of bidirectional promoters. As we mentioned above, nearly all genes in this class contain CpG islands, exclude TATA boxes and are enriched in binding sites for Myc, GABPA, E2F-1, E2F-4 and the CCAAT box 35, 45 , all of which have been characterized and studied in the bidirectional BRCA1 promoter 6, [8] [9] [10] 25, 34 . A second common feature of bidirectional promoters is their high enrichment in activating histone marks and poised RNA polymerases, suggesting that their chromatin structure is more open than that of other gene classes 35 . This is consistent with our findings here demonstrating that the resting BRCA1 promoter is already occupied by a poised Pol II and p300 complex, maintains constitutive histone marks associated with transcriptional activation, and is highly accessible to nuclease digestion in comparison to β-globin in MCF-7 cells. This is also consistent with genome-wide studies indicating that certain classes of genes containing CpG islands already have destabilized nucleosomes in their proximal promoter and therefore have reduced requirements for chromatin remodeling factors during activation 46 . These (b) Schematic hypothetical model for mechanism of CtBP control of BRCA1 transcription. The nucleosome positioning is as described 39 by the genome-wide sequencing of micrococcal nucleasegenerated fragments (MNase-seq). E2, changing NAD + /NADH ratio, CtBP knockdown or TSA treatment induces removal or inactivation of a repressive complex composed of CtBP, BRCA1, HDAC1 and HDAC2 at the dual BRCA1 promoter. Acetylation-associated destabilization of the centrally positioned nucleosome (Nuc), in combination with the asymmetric nucleosome distribution at the BRCA1 locus, biases expression more toward BRCA1 compared to NBR2 in response to the activating signals. A r t i c l e s properties are highly consistent with what we have observed at the BRCA1 promoter, where a central destabilized nucleosome provides a major means of control of BRCA1 transcription through regulation of chromatin marks via histone acetylation. The preloading of Pol II and p300 at the BRCA1 promoter indicates that subsequent postrecruitment steps have an important role in BRCA1 transcriptional regulation. One such step in the transcription cycle is elongation. Recent studies link histone acetylation and the recruitment of HAT activity to transcriptional elongation, possibly through recruitment of P-TEFb by factors like bromodomain protein 4 (Brd4) 47, 48 , or the 14-3-3 adaptor proteins, which bind to phosphoacetylated histone tails to enhance recruitment of other HAT activity to targeted promoters 49 . We observe recruitment of both P-TEFb and ELL to the BRCA1 promoter and transcribed regions after estrogen induction, suggesting an intimate association among these factors and chromatin modification during estrogen induction. It will be important to explore in future studies how estrogen-induced chromatin modification facilitates elongation events. Another important area in post-recruitment regulation of BRCA1 will be the role of CtBP in long-range changes in chromatin structure at the BRCA1 promoter. Lost spatial interactions between the promoter and the terminator region of BRCA1 after estrogen stimulation may induce BRCA1 expression 50 . Though we do not detect any interaction between CtBP and the terminator region of the BRCA1 locus, a possible role of the CtBP repressor complex in chromatin looping will be an important area for future investigation.
Multiple modes of estrogen stimulation of the BRCA1 promoter
The precise manner in which estrogen stimulates the BRCA1 promoter remains a matter of debate. A general consensus is that estrogen stimulates BRCA1 through an indirect response based on S-phase entry secondary to mitogenic genomic and nongenomic responses caused by estrogen stimulation (for example, RAS-MAP kinase signaling) 13, 14, 51 . Moreover, multiple genome-wide studies of estrogen receptor-binding sites by ChIP have failed to detect direct binding of estrogen receptor to the BRCA1 promoter 52 . However several groups have proposed that regulation could involve direct association of estrogen receptor via a binding site with weak homology to an estrogen response element (ERE) in the downstream alternate BRCA1 promoter (1b) or through tethering to AP1 or aromatic hydrocarbon receptor-binding sites 6, 34, 53, 54 . Regardless of these disputed points, none of the mechanisms described above for estrogen stimulation are mutually exclusive and all would be subject to titrated regulation by the assembly and release of the coactivator and co-repressor complexes described in this work.
Does CtBP participate in feedback control of estrogen stimulation?
The estrogen receptor and BRCA1 have a complex relationship in estrogen-responsive tissues 16 . Estrogen induces proliferation and activates BRCA1 functions in a negative-feedback loop to control or restrain the effects of estrogen by targeting estrogen-controlled genes, many of which are also controlled by p300 coactivation 55 . Therefore NADH consumption, secondary to estrogen-induced proliferation, would probably activate BRCA1 expression through dismissal of CtBP-HDAC1 complexes from the BRCA1 promoter. This is consistent with the observation that BRCA1 expression is highest in proliferating tissues 56 . Notably, many sporadic breast cancers that show decreased levels of BRCA1 expression also share gene expression profiles very similar to those exhibited by basal-like subtypes of breast cancer, which express markers normally associated with myoepithelial cells; this tumor phenotype most frequently arises in patients with germline mutations of BRCA1 (ref.
3). A feature common to the basal-like phenotype is the loss of markers associated with epithelial differentiation and the acquisition of features that promote motility and invasiveness. Notably, this BRCA-like phenotype is very similar to that seen in breast-derived epithelial cells undergoing epithelial-to-mesenchymal transition (EMT) 57 , a process frequently associated with overexpression of CtBP 17 . It is therefore probable that CtBP overexpression may have a role in a variety of malignancies by antagonizing the expression of BRCA1 and other tumor suppressor genes during tumor progression 17 .
High calories, estrogen, CtBP1 and BRCA1-a perfect storm?
There is a strong correlation among pre-and post-menopausal high caloric intake, weight gain and obesity and increased risk for breast cancer 58 . The physiological factors associated with increased risk involve elevated levels of extragonadal production of circulating and mammary estrogen due to aromatase present in fatty tissues of the breast and throughout the body. The elevated expression of estrogen in the context of higher levels of NADH or lower NAD + /NADH ratios due to high caloric intake and/or obesity could establish a state in which the pro-proliferative effects of estrogen are not completely balanced by the protective functions of BRCA1 that would normally restrain estrogen-induced proliferation and heighten genome surveillance. We speculate that the enhanced CtBP activity in mammary tissues with lower NAD + /NADH ratios, secondary to high caloric diet or obesity, may contribute to the increased risk for malignancies of the breast. In this regard, it would also be of interest to ascertain what percentage of postmenopausal breast cancer cases associated with pre-or post-menopausal weight gain or obesity show the basal-like phenotype associated with BRCA1 deficiency and/or germline mutation.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
